Impact Partnership Wealth LLC purchased a new stake in CVS Health Corporation (NYSE:CVS – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,573 shares of the pharmacy operator’s stock, valued at approximately $400,000.
Several other hedge funds have also added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd grew its stake in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares during the period. Swiss RE Ltd. acquired a new stake in shares of CVS Health during the fourth quarter worth about $26,000. Sankala Group LLC bought a new position in shares of CVS Health during the 4th quarter valued at about $28,000. Mcguire Capital Advisors Inc. bought a new position in shares of CVS Health during the 4th quarter valued at about $28,000. Finally, Ares Financial Consulting LLC acquired a new position in shares of CVS Health in the 4th quarter valued at approximately $29,000. Institutional investors and hedge funds own 80.66% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts have commented on CVS shares. Wells Fargo & Company raised their target price on shares of CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. JPMorgan Chase & Co. upped their price target on shares of CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Truist Financial increased their price objective on shares of CVS Health from $102.00 to $108.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. Barclays raised their price objective on shares of CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a report on Tuesday, May 26th. Finally, Morgan Stanley upped their target price on shares of CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research note on Thursday, June 4th. Twenty-one equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and an average price target of $101.28.
Insiders Place Their Bets
In other news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. This represents a 24.20% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 3,441,551 shares of company stock valued at $323,703,977. 0.85% of the stock is owned by insiders.
Key Headlines Impacting CVS Health
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: Analysts highlighted CVS Health’s strong earnings surprise track record and said the company appears positioned to beat estimates again in its next quarterly report, which supports sentiment around future profits. Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
- Positive Sentiment: CVS was also featured in a CNBC report about Medicare beginning to cover obesity drugs, with CVS and Walmart helping seniors navigate the new coverage landscape, underscoring CVS’s role in a growing healthcare service area. Healthy Returns: Walmart, CVS step in to help seniors navigate Medicare coverage of obesity drugs
- Positive Sentiment: CVS Health also published consumer-health content on women’s health and preventive screenings, reinforcing its push to drive pharmacy, clinic, and health-services engagement. CVS Health: A Menopause Revolution Is Long Overdue
- Positive Sentiment: An executive from CVS Health was named to Choice Hotels’ board, which is a small signal of leadership visibility and management credibility. Choice Hotels International Appoints Artificial Intelligence Leader Ali Keshavarz to Board of Directors
- Neutral Sentiment: A healthcare-advice article said UnitedHealth, Humana, and CVS denied post-hospital care at some of the highest rates, which could keep attention on utilization management and prior-authorization practices, but the piece does not provide a direct financial update. UnitedHealth, Humana, CVS Denied Post-Hospital Care At Some Of The Highest Rates
- Neutral Sentiment: CVS also appeared in coverage of its support for America250, which is mainly a branding/community-relations item and likely has limited near-term stock impact. CVS Health Exec Explains Why Its Support of America250 is ‘Natural Fit’
CVS Health Trading Up 1.3%
NYSE:CVS opened at $104.83 on Thursday. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $106.15. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The business has a 50 day moving average price of $93.44 and a two-hundred day moving average price of $82.96. The company has a market cap of $133.75 billion, a P/E ratio of 46.18, a price-to-earnings-growth ratio of 1.01 and a beta of 0.60.
CVS Health (NYSE:CVS – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, analysts expect that CVS Health Corporation will post 7.44 EPS for the current fiscal year.
CVS Health Company Profile
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Featured Stories
- Five stocks we like better than CVS Health
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
